Side-effects: latest news

Side-effects resources

  • Antiretroviral drugs chart

    A one-page reference guide to the anti-HIV drugs licensed for use in the European Union, with information on formulation, dosing, key side-effects and food restrictions....

    From: Antiretroviral drugs chart

    Information level Level 1
  • Side-effects

    Like all medications, anti-HIV drugs can cause side-effects and these can be a reason why people don’t take their treatment properly. The risk of side-effects can vary between...

    From: Booklets

    Information level Level 2
  • Side-effects

    Like all medication, anti-HIV drugs can have side-effects. Read more here on what these are and how to deal with them if you experience side-effects....

    From: Living with HIV

    Information level Level 2
  • Side-effects

    The booklet provides information about possible side-effects of HIV treatment. ...

    From: Booklets

    Information level Level 2
  • My drugs chart

    My drugs chart provides information on all the anti-HIV drugs currently licensed for use in Europe.Select your chosen drugs and drag them onto the area...

    From: My drugs chart

  • Side-effects

    We take medicines to make us better or to keep us well, but all medicines can cause unwanted secondary effects. These are usually called side-effects,...

    From: Factsheets

    Information level Level 2
  • Neuropathy - nerve pain

    Neuropathy is damage to the nerves. Nerves transmit signals within the brain and spinal cord (the central nervous system or CNS), and extend from the...

    From: Factsheets

    Information level Level 2
  • Facial wasting

    New cases of facial wasting caused by anti-HIV drugs are now rare in the UK.Fat loss from the face is one of the components of...

    From: Factsheets

    Information level Level 2
  • Hyperbilirubinaemia

    Bilirubin is a waste product produced by the liver during the breakdown of old red blood cells. The technical term for abnormally high levels of...

    From: Factsheets

    Information level Level 2
  • Lactic acidosis

    Lactic acidosis is a serious side-effect of the nucleoside reverse transcriptase inhibitor (NRTI) class of anti-HIV drugs. This class includes AZT (zidovudine, Retrovir), 3TC (lamivudine, Epivir), d4T...

    From: Factsheets

    Information level Level 2
  • Skin problems

    There are three main causes of skin problems in people with HIV: interactions between the immune system and HIV, infections, and side-effects of drugs. Some...

    From: Factsheets

    Information level Level 2
  • Pain

    Every day most of us will experience physical pain of some sort. For the most part it will cause only minor discomfort and won’t interfere...

    From: Factsheets

    Information level Level 2
  • Nausea and vomiting

    Nausea is a word for the feeling of wanting to vomit or be sick. Most people with HIV will experience nausea and vomiting at some...

    From: Factsheets

    Information level Level 2
  • Diarrhoea

    Diarrhoea is common among people with HIV. It can be a side-effect of anti-HIV drugs as well as some other medicines, such as antibiotics. Diarrhoea...

    From: Factsheets

    Information level Level 2
  • Tiredness and fatigue

    Tiredness and fatigue are common problems among people with HIV. There are many possible causes and treatments and there are also things you can do...

    From: Factsheets

    Information level Level 2
  • Changing treatment due to side-effects

    All drugs can cause side-effects and the drugs used in treating HIV are no exception. Changing treatment because of side-effects is quite common. ...

    From: Factsheets

    Information level Level 2
  • Side effects

    The most common side effects are the result of your body getting used to a new drug. After a few weeks, these side effects usually...

    From: The basics

    Information level Level 1
  • Lipodystrophy

    Lipodystrophy (lip-oh-diss-troh-fee) is the name for changes in body shape first reported in 1997 among people taking HIV treatment. It was originally thought that the...

    From: Factsheets

    Information level Level 2
  • Side-effects

    Information on the side-effects associated with anti-HIV treatments and other drugs, including advice on how to cope with them, and whether treatment should be stopped...

    From: HIV treatments directory

    Information level Level 4
  • Effect of genetic variation on side-effects of HIV drugs

    In addition to drug levels, the other major area of research interest in pharmacogenetics is the association of human genetic variation with the incidence or...

    From: HIV treatments directory

    Information level Level 4
  • Your shape

    This booklet covers the side effects of fat loss, fat gain, raised blood fats and raised blood sugars....

    From: 'Your' booklets series

    Information level Level 1
  • Your treatment

    This booklet gives a basic, but comprehensive introduction to HIV treatment....

    From: 'Your' booklets series

    Information level Level 1

Side-effects features

Side-effects in your own words

Side-effects news from aidsmap

More news

Side-effects news selected from other sources

  • Drug that reduces abdominal fat in HIV patients also may reduce fat in liver

    The only drug to receive Food and Drug Administration approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. Massachusetts General Hospital investigators report that six months of daily injections of tesamorelin significantly reduced fat in the liver without affecting glucose metabolism.

    19 July 2014 | Eurekalert Medicine & Health
  • Common HIV Drug May Boost Suicide Risk

    A medication commonly used to treat HIV appears to double the risk that patients will develop suicidal thoughts or take their lives, new research contends. The finding concerns the anti-HIV drug efavirenz, which is marketed as Sustiva.

    02 July 2014 | Web MD
  • Lowering toxicity of new HIV drugs predicted to improve life expectancy

    While bringing new drugs to market is important for increasing life expectancy in younger people with HIV, lowering the toxicity of those drugs may have an even greater health impact on all HIV patients, a University of Pittsburgh Graduate School of Public Health analysis reveals.

    26 June 2014 | EurekAlert
  • In HIV/TB coinfection, raltegravir may be an alternative to efavirenz

    Patients coinfected with HIV and tuberculosis (TB) may benefit from raltegravir as an alternative to efavirenz, new research suggests.

    02 June 2014 | Medscape
  • ART use not linked to advanced kidney disease in 35,000 with HIV

    Neither current nor recent use of tenofovir or any other antiretroviral therapy (ART) predicted advanced chronic kidney disease (CKD) or end-stage renal disease (ESRD) in a study or more than 35,000 adults with HIV infection.

    12 February 2014 | International AIDS Society
  • What ‘Dallas Buyers Club’ got wrong about the AIDS crisis

    'Tis the season for Oscar bait, and this year, "Dallas Buyers Club" looks set to get at least a few nominations. The movie stars Matthew McConaughey as Ron Woodroof, a Dallas man who contracts HIV in 1985, when the diagnosis was a death sentence. But it risks leaving a false impression of that period in the history of HIV/AIDS, and in particular of the role of AZT.

    11 December 2013 | Washington Post
  • Unusual and rare complication described in San Francisco

    Doctors in San Francisco have reported an unusual and rare finding—an apparently harmless but disfiguring condition called cutis verticis gyrata (CVG) on the heads of four HIV-positive men. In CVG, the skin on the head becomes raised in parts and depressed in others, forming ridges and furrows.

    09 December 2013 | CATIE
  • Differing Effects of Low- and High-Fat Meals on New Raltegravir Formulation

    A high-fat meal affected levels of a reformulated raltegravir tablet less than a low-fat meal, according to results of a three-period study in healthy volunteers [1]. One aim of this trial and other ongoing research is to develop a raltegravir formulation that can be dosed once daily.

    30 October 2013 | NATAP
  • Crofelemer effective for severe or PI-related diarrhea in placebo trial

    Crofelemer, a botanically derived agent indicated for symptomatic relief of noninfectious diarrhea in antiretroviral-treated people, proved particularly effective against severe, intransigent diarrhea and protease inhibitor (PI)-related diarrhea in subgroup analyses of a double-blind placebo-controlled trial.

    19 September 2013 | NATAP
  • Switching From Efavirenz to Rilpivirine Combo Quells CNS Side Effects

    Swapping efavirenz-containing Atripla for rilpivirine-containing Complera (Eviplera in Europe) significantly lowered rates of central nervous system (CNS) side effects and sleep disturbances in a 40-person multicenter pilot trial.

    13 September 2013 | NATAP
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.